HC Wainwright Issues Positive Outlook for ACRS Earnings

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Equities research analysts at HC Wainwright increased their Q1 2026 earnings per share (EPS) estimates for shares of Aclaris Therapeutics in a research report issued on Thursday, March 19th. HC Wainwright analyst R. Selvaraju now forecasts that the biotechnology company will post earnings of ($0.14) per share for the quarter, up from their previous forecast of ($0.15). HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.82) per share. HC Wainwright also issued estimates for Aclaris Therapeutics’ Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.11) EPS, Q4 2026 earnings at ($0.10) EPS, FY2026 earnings at ($0.48) EPS, Q1 2027 earnings at ($0.11) EPS, Q2 2027 earnings at ($0.12) EPS, Q3 2027 earnings at ($0.13) EPS, Q4 2027 earnings at ($0.14) EPS and FY2027 earnings at ($0.50) EPS.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings results on Thursday, February 26th. The biotechnology company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.01). Aclaris Therapeutics had a negative net margin of 829.58% and a negative return on equity of 52.04%. The company had revenue of $1.30 million for the quarter, compared to analysts’ expectations of $2.07 million.

ACRS has been the subject of several other reports. Craig Hallum started coverage on shares of Aclaris Therapeutics in a report on Friday, January 30th. They set a “buy” rating and a $10.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Aclaris Therapeutics in a research report on Monday, December 29th. Finally, Wall Street Zen cut shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $9.80.

Aclaris Therapeutics Trading Down 7.8%

Aclaris Therapeutics stock opened at $3.30 on Monday. The firm has a market cap of $397.98 million, a PE ratio of -6.23 and a beta of 0.88. Aclaris Therapeutics has a 12 month low of $1.05 and a 12 month high of $4.89. The stock’s 50 day simple moving average is $3.44 and its two-hundred day simple moving average is $2.80.

Institutional Investors Weigh In On Aclaris Therapeutics

A number of institutional investors have recently added to or reduced their stakes in ACRS. R Squared Ltd acquired a new position in Aclaris Therapeutics during the fourth quarter worth $37,000. AXQ Capital LP acquired a new stake in shares of Aclaris Therapeutics in the third quarter valued at about $27,000. CIBC Asset Management Inc acquired a new stake in shares of Aclaris Therapeutics in the fourth quarter valued at about $52,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Aclaris Therapeutics during the fourth quarter worth about $53,000. Finally, ProShare Advisors LLC purchased a new stake in shares of Aclaris Therapeutics during the second quarter worth about $26,000. Institutional investors and hedge funds own 98.34% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.